BSE filing, BSE: 544353. Summary written from the filing by ALFA Finder's alert engine.
Amwill Health Care Ltd: key numbers
- Share price
- ₹42.10
- Market cap
- ₹84.22 Cr
- Revenue (annual)
- ₹45.49 Cr
- Net profit (annual)
- ₹11.42 Cr
- P/E (TTM)
- 7.4×Sector 47.2×
- Promoter holding
- 70.65%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amwill Health Care Ltd
All →Amwill Health Care Dividend
Amwill Health Care's board declared an interim dividend of Rs.0.05 per equity share for FY 2026-27 on 23 October 2026. The record date is 30 October 2026 and payment is proposed by 22 November 2026.
Amwill Health Care H1 FY27 Results: Net Profit ₹3.7 Cr, Down 50.7% YoY
Amwill Health Care Ltd reported revenue from operations of ₹22.6 Cr (-7.0% YoY) and net profit of ₹3.7 Cr (-50.7% YoY) for H1 FY27.
- Key figure
- Net profit ₹3.7 Cr · -50.7% YoY
Amwill Health Care Board Meeting Date
Amwill Health Care has scheduled a board meeting for October 23, 2026, to review H1 financial results and consider declaring an interim dividend.
Amwill Health Care Other Announcement
This filing is a standard quarterly Shareholding Pattern submission in accordance with SEBI Regulation 31(1)(b) for Amwill Health Care Ltd as of September 30, 2026.
Amwill Health Care Acquisition Worth ₹3 Cr
Amwill Health Care Limited approved investments of ₹3 Crore into two Alternative Investment Funds. The company will invest ₹1.50 Crore each in Vivriti Vihaan Trust and Neo Income Plus Fund III.
- Value
- ₹3.00 Cr
- Execution
- Ensuing month(s)
Amwill Health Care Management Change
Amwill Health Care Ltd re-appointed Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term, effective January 27, 2027.
- Execution
- 5 years
Other regulatory approval announcements
All →City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.
Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.